Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo

被引:195
作者
Robles, AI
Rodriguez-Puebla, ML
Glick, AB
Trempus, C
Hansen, L
Sicinski, P
Tennant, RW
Weinberg, RA
Yuspa, SH
Conti, CJ [1 ]
机构
[1] Univ Texas, MD Anderson Cancer Ctr, Sci Pk Res Div, Smithville, TX 78957 USA
[2] NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bethesda, MD 20892 USA
[3] NIEHS, Lab Environm Carcinogenesis & Mutagenesis, Res Triangle Pk, NC 27709 USA
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
[6] MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[7] MIT, Dept Biol, Cambridge, MA 02142 USA
关键词
knockout; Tg.AC; cell cycle; keratinocyte; two-stage carcinogenesis;
D O I
10.1101/gad.12.16.2469
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cyclin D1 is part of a cell cycle control node consistently deregulated in most human cancers. However, studies with cyclin D1-null mice indicate that it is dispensable for normal mouse development as well as eel growth in culture. Here, rye provide evidence that ras-mediated tumorigenesis depends on signaling pathways that act preferentially through cyclin D1. Cyclin D1 expression and the activity of its associated kinase are up-regulated in keratinocytes in response to oncogenic ras. Furthermore, cyclin D1 deficiency results in up to an 80% decrease in the development of squamous tumors generated through either grafting of retroviral ras-transduced keratinocytes, phorbol ester treatment of ras transgenic mice, or two-stage carcinogenesis.
引用
收藏
页码:2469 / 2474
页数:6
相关论文
共 35 条
[1]   ABERRATIONS OF P16(INK4) AND RETINOBLASTOMA TUMOR-SUPPRESSOR GENES OCCUR IN DISTINCT SUB-SETS OF HUMAN CANCER CELL-LINES [J].
AAGAARD, L ;
LUKAS, J ;
BARTKOVA, J ;
KJERULFF, AA ;
STRAUSS, M ;
BARTEK, J .
INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (01) :115-120
[2]   TRANSFORMING P21(RAS) MUTANTS AND C-ETS-2 ACTIVATE THE CYCLIN D1 PROMOTER THROUGH DISTINGUISHABLE REGIONS [J].
ALBANESE, C ;
JOHNSON, J ;
WATANABE, G ;
EKLUND, N ;
VU, D ;
ARNOLD, A ;
PESTELL, RG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) :23589-23597
[3]   THE PRAD-1 CYCLIN D1 ONCOGENE PRODUCT ACCUMULATES ABERRANTLY IN A SUBSET OF COLORECTAL CARCINOMAS [J].
BARTKOVA, J ;
LUKAS, J ;
STRAUSS, M ;
BARTEK, J .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (04) :568-573
[4]  
BIANCHI AB, 1993, ONCOGENE, V8, P1127
[5]  
DLUGOSZ AA, 1994, CELL GROWTH DIFFER, V5, P1283
[6]  
Dlugosz AA, 1997, CANCER RES, V57, P3180
[7]  
DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3
[8]   THE INHIBITION OF EGF-DEPENDENT PROLIFERATION OF KERATINOCYTES BY TYRPHOSTIN TYROSINE KINASE BLOCKERS [J].
DVIR, A ;
MILNER, Y ;
CHOMSKY, O ;
GILON, C ;
GAZIT, A ;
LEVITZKI, A .
JOURNAL OF CELL BIOLOGY, 1991, 113 (04) :857-865
[9]   MICE LACKING CYCLIN D1 ARE SMALL AND SHOW DEFECTS IN EYE AND MAMMARY-GLAND DEVELOPMENT [J].
FANTL, V ;
STAMP, G ;
ANDREWS, A ;
ROSEWELL, I ;
DICKSON, C .
GENES & DEVELOPMENT, 1995, 9 (19) :2364-2372
[10]  
FILMUS J, 1994, ONCOGENE, V9, P3627